The second Medical Center of PLA general hospital
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lu, Xuechun
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

Recruiting
4
165
RoW
rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention
The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation
Cancer Treatment Induced Thrombocytopenia
06/24
08/24
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Completed
4
157
RoW
rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine
Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province
Previously Treated Primary Immune Thrombocytopenia
02/24
07/24
BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting
2
80
RoW
Activated CIK, CIK
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital
Advanced Liver Cancer
01/21
01/21
NCT05920512: Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.

Recruiting
1/2
10
RoW
Sodium valproate extended-release tablets, sirolimus tablets, calcitriol capsules
Xue-chun Lu
Hemophilia
04/25
04/25
Mao, Min
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Completed
4
157
RoW
rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine
Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province
Previously Treated Primary Immune Thrombocytopenia
02/24
07/24

Download Options